TOPAZ DENOISE 6 ACTION TUMBLR FREE

All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. Kessler Topaz Meltzer& Check, LLP encourages Cassava investors who have suffered significant losses to contact the firm directly to acquire more information.ДЄ lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The complaint alleges that throughout the Class Period, the defendants failed to disclose to investors that: (1) data underlying the foundational research for CassavaвЂ™s product candidates had been manipulated (2) experiments using post-mortem human brain tissue frozen for nearly 10 years was contrary to a basic understanding of neurobiology (3) biomarker analysis for patients treated with simufilam had been manipulated to conclude that simufilam was effective (4) Quanterix Corp., an independent company, had not interpreted the test results or prepared the data charts for the biomarker analysis for patients treated with simufilam (5) as a result of the foregoing, there was a reasonable likelihood that Cassava would face regulatory scrutiny in connection with the development of simufilam and (6) as a result of the foregoing, the defendantsвЂ™ positive statements about CassavaвЂ™s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.Д¬assava investors may, no later than October 26, 2021, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member.

Simufilam purportedly targets an altered form of a protein called filamin A (вЂњFLNAвЂќ) in the AlzheimerвЂ™s brain and reverts it to its native, healthy conformation, thereby countering the downstream toxic effects of altered FLNA.

Its lead therapeutic product candidate is called simufilam (formerly PTI-125) developed as a treatment for AlzheimerвЂ™s disease.

TOPAZ DENOISE 6 ACTION TUMBLR FREE

(484) 270-1453 or Toll Free (844) 887-9500 or Email at ALLEGED MISCONDUCTД¬assava is a clinical stage biotechnology company.

LEAD PLAINTIFF DEADLINE : October 26, 2021Д¬LASS PERIOD: Septemthrough August 27, 2021Д¬ONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS: ( NASDAQ: SAVA) (вЂњCassavaвЂќ) on behalf of those who purchased or acquired Cassava securities between Septemand August 27, 2021, inclusive (the вЂњClass PeriodвЂќ). RADNOR, Pa.вЂ“(BUSINESS WIRE)вЂ“ $SAVAвЂ“The law firm of Kessler Topaz Meltzer & Check, LLP announces to investors of upcoming lead plaintiff deadline in securities fraud class action lawsuit filed against Cassava Sciences, Inc.

Topaz denoise 6 action tumblr